NRG Scientific Session
NRG Oncology Research Review

Date: Friday, July 15, 2016
Start and End Time: 8:00 am – 10:00 am
Co-Chairs Deborah Bruner, PhD; Fred Stehman, MD; Maria Werner Wasik, MD
Moderator Maria Werner Wasik, MD

Learning Objectives: Following this activity, participants will be better able to:

1. Describe the findings of the recent interim analysis conducted on the multi-arm phase II NCI-MATCH precision medicine cancer trial that defines patient eligibility by molecular characteristics of the tumor rather than tumor type, and explain the changes made to the trial as a result of the analysis.
2. Discuss the interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer.
3. Discuss the role of anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA for prostate cancer patients.
4. Describe mutations in homologous recombination genes and response to treatment as found in GOG 218.
5. Identify the correlation between the severity of cetuximab-induced skin rash and clinical outcome for head and neck cancer patients.

AGENDA

8:00 – 8:05 am Welcome
     Maria Werner-Wasik, MD

8:05 – 8:20 am NCI’s National Clinical Trial Network (NCTN) Study Champion Program and Implementation
     Andrea Denicoff, MS, RN, ANP

8:20 – 8:39 am Interim analysis results of the NCI’s Molecular Analysis for Therapy Choice (NCI-MATCH) Trial
     Eddy S. Yang, MD, PhD

8:39-8:44 am Questions

8:44 – 8:59 am Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer.
     Joanne L Blum, MD

8:59 – 9:07 am Discussant & Questions
     William Sikov, MD

9:07 – 9:22 am NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA.
     William Shipley, MD

9:22 – 9:30 am Discussant-Questions
     Mark Buyyounouski, MD

9:30 – 9:45 am Mutations in homologous recombination genes and response to treatment in GOG 218: An NRG Oncology study.
     Barbara Norquist

Questions

9:45 – 10:00 am Correlation between the severity of cetuximab-induced skin rash and clinical outcome for head and neck cancer patients: The NRG Oncology RTOG experience.
     Voichita Bar-Ad, MD

Questions